Fig. 7: GLUD2 mutation modulates BDNF and Nrf2 expression in MPTP-treated mice and MPP+-treated U251 cells.
From: Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
a Ultrastructural analysis of mitochondria in the SN of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars, upper, 2 µm; lower, 500 nm). The black arrows indicated the normal mitochondria, and the red arrows indicated the damaged mitochondria. b, c Effect of GLUD2 or its mutant on BDNF and Nrf2 expression in the SN of MPTP-treated mice or in MPP+-treated U251 cells was determined by western blotting. n = 6 in (b) and n = 3 in (c). d Immunofluorescent staining of GFP and BDNF in the SNpc of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars: upper, 40 µm; lower, 8 µm). e Immunofluorescent staining of GFP, GFAP, and Nrf2 in the SNpc of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars, upper, 40 µm; lower, 8 µm). Results are expressed as the mean ± SEM. **p < 0.01 vs. AAV-GFP or untreated U251 cell group. ##p < 0.01, #p < 0.05 vs. MPTP + AAV-GFP or MPP+ group. &&p < 0.01, &p < 0.05 vs. MPTP + AAV-GLUD2 group. Statistical significance was determined by one-way ANOVAs and Tukey tests for post-hoc comparisons.
